Search

“I can see fine. Why do I need my eyes tested?”

Are routine eye examinations really necessary? The author asks whether frequent appointments in low-risk patients with normal results are actually cost-effective. It’s recommended that most people should get their eyes tested every two years.” [1] This message is widely publicised...

An eye on novel anti-cancer agents: an evidence-based approach to external eye assessment

Novel anti-cancer therapies have led to significant advancement in cancer treatment, however, they can be associated with external eye complications. It is important to be mindful of such adverse effects during assessment of patients enrolled in clinical trials. Annually, approximately...

The sexist lens addressing cataract-induced blindness in women

Ninety percent of the world’s blind population resides in low-income, developing countries [1]. The primary cause of their blindness is cataract, a condition that is easily treatable and unnecessary. A cataract is the clouding of the eye’s lens, often resulting...

Imaging papilloedema vs. pseudo-papilloedema

Quite often, in the working week as an ophthalmic photographer, you will be given that patient with ‘swollen discs’ to image. These swollen discs could be a number of things, but mainly fall into one of two categories: papilloedema or...

AI & Oculomics: a new section for Eye News

Inaugurating this new regular section on the exciting landscape of AI and oculomics, we provide an overview which delves into the historical context and the etymology of this field, reviews the current state of play and contemplates possibilities and hopes...

Semaglutide and vision loss: A new concern for NAION risk?

This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as transformative agents in...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Eyeviews Podcast

eyeviews presents conversations on seeing and sight loss, released by Eye News magazine. Hosted by Lorcan Butler, this podcast covers a wide and diverse range of topics related to ophthalmology, optometry and more. Eye Views is available on Spotify, Apple...